Grabowska, J.; Stolk, D.A.; Nijen Twilhaar, M.K.; Ambrosini, M.; Storm, G.; van der Vliet, H.J.; de Gruijl, T.D.; van Kooyk, Y.; den Haan, J.M.M.
Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. Vaccines 2021, 9, 56.
https://doi.org/10.3390/vaccines9010056
AMA Style
Grabowska J, Stolk DA, Nijen Twilhaar MK, Ambrosini M, Storm G, van der Vliet HJ, de Gruijl TD, van Kooyk Y, den Haan JMM.
Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. Vaccines. 2021; 9(1):56.
https://doi.org/10.3390/vaccines9010056
Chicago/Turabian Style
Grabowska, Joanna, Dorian A. Stolk, Maarten K. Nijen Twilhaar, Martino Ambrosini, Gert Storm, Hans J. van der Vliet, Tanja D. de Gruijl, Yvette van Kooyk, and Joke M.M. den Haan.
2021. "Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1" Vaccines 9, no. 1: 56.
https://doi.org/10.3390/vaccines9010056
APA Style
Grabowska, J., Stolk, D. A., Nijen Twilhaar, M. K., Ambrosini, M., Storm, G., van der Vliet, H. J., de Gruijl, T. D., van Kooyk, Y., & den Haan, J. M. M.
(2021). Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. Vaccines, 9(1), 56.
https://doi.org/10.3390/vaccines9010056